FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nachington	$D \subset$	20540	
Nashington,	D.C.	20549	

STATEMENT	OF CHANGE	S IN BENEF	ICIAL (	OWNERSHI	P

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Hammond Janet MJ				2. Issuer Name and Ticker or Trading Symbol Atea Pharmaceuticals, Inc. [ AVIR ]						(Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify												
(Last)	(F NKLIN ST	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/31/2024						X	below)  Chief Development Officer											
SUITE 2										Line)	<b>'</b>												
(Street) BOSTO	N M	ſΑ	02110								X	X Form filed by One Reporting Person Form filed by More than One Reporting Person											
(City)	(8	State)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							atisfy the											
		Т	able I - Non	-Deriva	tive S	ecuriti	es Acq	uired,	Dis	posed of	, or Ben	eficially	Owned										
			2. Transact Date Month/Day	Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		(A) or 3, 4 and 5)	nd 5) Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership										
							Code	v	Amount	(A) or (D)	Price		nsaction(s) str. 3 and 4)		,	(Instr. 4)							
Common	Stock	01/			2024			M		46,800	A	(1)	49,39	<b>)</b> 1 <sup>(2)</sup>		D							
Common Stock 02			02/01/2	/2024		S		14,029 <sup>(3)</sup> D		\$3.843	35,362		2 D										
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code		Derivative Expiration Date (Month/Day/Year) Acquired (A) or		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	itive Own ities For- icially Dire d or li ving (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)									
				Code	v	(A)	(D)	Date Exercisable						Expiration Date	Title	Amount or Number of Shares		Transact (Instr. 4)					
Restricted Stock Units	(1)	01/31/2024		М			46,800	(4)		(4)		(4)		(4)		(4)	Common Stock	46,800	\$0.00	93,60	00	D	
Stock Option (Right to Buy)	\$4.16	01/31/2024		A		225,200		(5)		(5)		(5)		01/30/2034	Common Stock	225,200	\$0	225,2	00	D			

## **Explanation of Responses:**

- $1. \ Each \ restricted \ stock \ unit \ ("RSU") \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ Common \ Stock.$
- 2. Includes 2,591 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
- 3. Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
- 4. The original grant of 140,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
- 5. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.

/s/ Andrea Corcoran, as

Attorney-in-Fact for Janet

**Hammond** 

\*\* Signature of Reporting Person Date

02/02/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.